Ongoing clinical trials testing the activity of ADCs in patients with brain metastases or LMD. Hope to see even more inclusion in clinical trials moving forward - not only in breast cancer, but in other solid tumors as well!

If you are supporting a friend or loved one who is living with #MBC, please consider joining us in this interactive, virtual social gathering - Wednesday May 15 at 6:30 pm Eastern Time - And a big thank you for the invaluable support and care you provide!

Key findings from analysis of outcomes to 1L anti-HER2 therapy in those with HER2+ MBC within ESME cohort -25% progression free at 3y -Of pts progression-free at 3y, 68% will remain progression-free at 5y -biomarkers needed to identify these pts upfront

Updated data for Pfizer cdk4-selective inhibitor PF-07220060 -pt population: 100% prior cdk4/6i -favorable tox profile -32% ORR, median PFS 8.1 mo -efficacy regardless of ESR1 and PIK3CA mutation status

To my amazing brother-(in law): visionary scientist, incredible mentor, loving husband and father - ❤️❤️❤️ He’s lifted up so many. So fitting for a YIA to be dedicated to him and moving to see such an outpouring of support - Please donate if you can …

May is #BrainTumorAwarnessMonth and May 20th is #InternationalClinicalTrialsDay - hence we are highlighting the much needed #clinicaltrials for patients with #BreastCancerBrainMetastases. #BCBM #BrianMets #bcsm Check out our research page to learn more↙️ dana-farber.org/cancer-care/tr…

#PatientAdvocates attending #ASCO24. Note events, hours, & new location of PA Lounge - S404. Join me, alongside Dr. Erica Mayer (Erica Mayer) & ASCO Clinical Division Director, Pam Mangat: 6/2- 8:00 - 9:00 am CT, to learn about the The Patient-Centered Outcomes Research Institute funded ASCO CDK Dosing Study! #bcsm

We start #ASCO24 tomorrow. Another wonderful opportunity to contribute to ASCO’ s mission by donating to Conquer Cancer, the ASCO Foundation —my personal favorite is the Felix Feng #ASCOYIA —please donate: p2p.conquer.org/uniteandconque… UCSF Health Karen Knudsen, MBA PhD Mary Feng Josh Lang

Congratulations to Drs. Ana Garrido-Castro, ⁦Nolan Priedigkeit, Nolan Priedigkeit⁩ and ⁦Ines Vaz Luis⁩, and all other recipients for their well deserved awards! Please donate to this good cause! ⁦Conquer Cancer, the ASCO Foundation⁩ support.conquer.org/page/56824/don…

This should be a great session! "Navigating the Complexities of Brain Mets Management." Saturday June 1 at 4:45pm CDT in E450a at ASCO! Hussein Tawbi, MD, PhD

Terrific presentation from Daniel Kates-Harbeck showing the potential for multimodal AI models to predict prognosis in HR+ breast ca w/in WSG PlanB and ADAPT. ⁦Adds to prognostication beyond traditional clin-path factors ⁦ArteraAI⁩ ⁦⁦Nadia Harbeck,MD PhD⁩

I couldn’t be more happy for Dr. Ines Vaz Luis. She is the epitome of “pay it forward” and has put her heart and soul into mentoring and elevating the next generation, with a focus on patient-centered outcomes and care. Congratulations Ines!!

Love seeing our former and current ⁦Dana-Farber’s Breast Oncology Center⁩ intl fellows thriving! ⁦ ⁦⁦Guilherme Nader Marta⁩,Ana Garrido-Castro, ⁦Romualdo Barroso, MD PhD⁩, ⁦⁦⁦Antonio Di Meglio, MD, PhD⁩ , ⁦⁦Sonia Pernas⁩ , ⁦⁦Ines Vaz Luis⁩ , ⁦Pedro Exman MD, PhD⁩, Pietro De Placido

TBCRC 049: Tucatinib, trastuzumab, capecitabine for HER2+ LMD -The first prospective LMD trial to show all of the following: -therapeutic drug levels in CSF -intracranial response -improvement in symptoms and QoL -extended OS compared to historical controls

Eye opening results from NADINA study in melanoma -preop Ipi/Nivo superior to adjuvant Ipi/nivo x 12 -2/3 of preop pts had a major response to just 2 cycles (6 wks) and did well w/o any additional adjuvant tx! -innovative study design and great news for pts

Why was the control arm lapatinib plus capecitabine given phase 3 PHOEBE study showing superiority of pyrotinib/cape over lap/cape and availability of pyrotinib in China?? thelancet.com/journals/lanon…

EAZ171: Prospective study of adj taxane in Black women ⬆️G2 or higher neuropathy with weekly paclitaxel vs Q3W docetaxel - 40% vs 24% ⬆️dose reductn for neuropathy w/P vs D (28% vs 9%) Highlights importance of diverse trial accrual to optimize tx ascopubs.org/doi/10.1200/JC…

So great to catch up in person with the wonderful and brilliant Dr Nadia Harbeck Nadia Harbeck,MD PhD at #ASCO24. #bcsm

Deep dive into the practicalities and barriers to bringing innovations to pts with brain mets and LMD at the 2024 SNO/ASCO CNS Metastases Conference Tatiana Prowell, MD Carey Anders Hussein Tawbi, MD, PhD

Join the EMBRACE Program for a day of wellness, education, and community building. The free event is open to adults living with #MetastaticBreastCancer and loved ones. #MBC 🗓️Fri Sept 20th from 10:00am to 2:30pm Dana-Farber ✍️Please RSVP by Aug 30 redcap.partners.org/redcap/surveys…